Kiniksa Pharmaceuticals
KNSA
104 hedge funds and large institutions have $442M invested in Kiniksa Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 55 increasing their positions, 15 reducing their positions, and 14 closing their positions.
267% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 15
64% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 14
17% more call options, than puts
Call options by funds: $1.49M | Put options by funds: $1.27M
8% more funds holding
Funds holding: 96 → 104 (+8)
7.21% more ownership
Funds ownership: 84.21% → 91.42% (+7.2%)
18% less capital invested
Capital invested by funds: $539M → $442M (-$96.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$21.8M |
| 2 |
Janus Henderson Group
London,
|
+$21M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.3M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$12.1M |
| 5 |
BlackRock
New York
|
+$11.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$10M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$8.8M |
| 3 |
EP
Eversept Partners
New York
|
-$2.08M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$1.28M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$1.27M |
KNSA Hedge Fund Activity: Q3 2020 in Review
104 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q3 2020, worth a combined $442M — down 18% from $539M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new KNSA positions and 14 closed out — a net gain of 9 holders — while 55 added to existing stakes and 15 trimmed.
The largest buyer was ArrowMark Colorado Holdings, opening a new position worth an estimated $21.8M. The largest seller was Sofinnova Investments, cutting an estimated $10M.
- 104 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q3 2020, up from 96 in Q2 2020.
- Funds reported $442M of Kiniksa Pharmaceuticals stock for Q3 2020, down 18% quarter-over-quarter.
- 23 funds opened new Kiniksa Pharmaceuticals positions in Q3 2020 and 14 closed out, a net change of +9 holders.
- The largest Kiniksa Pharmaceuticals buyer in Q3 2020 was ArrowMark Colorado Holdings, an estimated $21.8M added.
- The largest Kiniksa Pharmaceuticals seller in Q3 2020 was Sofinnova Investments, an estimated $10M sold.
Based on aggregated 13F filings for Q3 2020.